CL2015002624A1 - Agentes quelantes de precursores de producto final de glicación avanzada (age) - Google Patents

Agentes quelantes de precursores de producto final de glicación avanzada (age)

Info

Publication number
CL2015002624A1
CL2015002624A1 CL2015002624A CL2015002624A CL2015002624A1 CL 2015002624 A1 CL2015002624 A1 CL 2015002624A1 CL 2015002624 A CL2015002624 A CL 2015002624A CL 2015002624 A CL2015002624 A CL 2015002624A CL 2015002624 A1 CL2015002624 A1 CL 2015002624A1
Authority
CL
Chile
Prior art keywords
agents
age
end product
advanced glycation
glycation end
Prior art date
Application number
CL2015002624A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Randall Holmes-Farley
Pradeep Dhal
Magnus Besev
Robert J Miller
Andrew T Papoulis
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CL2015002624A1 publication Critical patent/CL2015002624A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2015002624A 2013-03-15 2015-09-11 Agentes quelantes de precursores de producto final de glicación avanzada (age) CL2015002624A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2015002624A1 true CL2015002624A1 (es) 2016-03-11

Family

ID=50439508

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002624A CL2015002624A1 (es) 2013-03-15 2015-09-11 Agentes quelantes de precursores de producto final de glicación avanzada (age)

Country Status (24)

Country Link
US (2) US20160024233A1 (enExample)
EP (1) EP2968403A1 (enExample)
JP (4) JP2016512830A (enExample)
KR (1) KR20150130492A (enExample)
CN (1) CN105188718A (enExample)
AR (1) AR095593A1 (enExample)
AU (2) AU2014235500A1 (enExample)
BR (1) BR112015023404A8 (enExample)
CA (1) CA2906501A1 (enExample)
CL (1) CL2015002624A1 (enExample)
CR (1) CR20150545A (enExample)
DO (1) DOP2015000221A (enExample)
EA (1) EA201591733A1 (enExample)
HK (1) HK1220607A1 (enExample)
IL (1) IL241406A0 (enExample)
MA (1) MA38487A1 (enExample)
MX (1) MX2015012843A (enExample)
PE (1) PE20151766A1 (enExample)
PH (1) PH12015502019A1 (enExample)
SG (2) SG10201707590XA (enExample)
TN (1) TN2015000390A1 (enExample)
TW (1) TW201521744A (enExample)
UY (1) UY35441A (enExample)
WO (1) WO2014150873A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
MX2020002048A (es) * 2017-08-31 2020-09-21 Cytosorbents Corp Reduccion de productos finales de glicacion avanzada a partir de fluidos corporales.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
WO2002085377A1 (en) * 2001-04-18 2002-10-31 Genzyme Corporation Method for lowering serum glucose
AU2003263010A1 (en) * 2003-09-02 2005-04-21 Genzyme Corporation Method for reducing vascular inflammation
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
EP1753861A4 (en) * 2004-02-17 2010-03-10 Dynamis Therapeutics Inc FRUCTOSAMINE-3-KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
ES2549513T3 (es) * 2010-02-24 2015-10-28 Relypsa, Inc. Polivinilamina, polialilamina y polietilenimina reticuladas para uso como secuestradores de ácidos biliares

Also Published As

Publication number Publication date
JP2022037143A (ja) 2022-03-08
IL241406A0 (en) 2015-11-30
CA2906501A1 (en) 2014-09-25
PH12015502019A1 (en) 2016-01-11
HK1220607A1 (zh) 2017-05-12
BR112015023404A8 (pt) 2019-12-03
WO2014150873A1 (en) 2014-09-25
AR095593A1 (es) 2015-10-28
EA201591733A1 (ru) 2016-01-29
JP2020055850A (ja) 2020-04-09
AU2014235500A1 (en) 2015-11-05
EP2968403A1 (en) 2016-01-20
US20160024233A1 (en) 2016-01-28
AU2019201259A1 (en) 2019-03-14
UY35441A (es) 2014-10-31
KR20150130492A (ko) 2015-11-23
SG11201506413PA (en) 2015-09-29
MA38487A1 (fr) 2017-12-29
PE20151766A1 (es) 2015-12-11
CR20150545A (es) 2015-12-01
MX2015012843A (es) 2016-08-08
BR112015023404A2 (pt) 2017-07-18
US20180265613A1 (en) 2018-09-20
SG10201707590XA (en) 2017-11-29
TW201521744A (zh) 2015-06-16
DOP2015000221A (es) 2015-12-15
CN105188718A (zh) 2015-12-23
TN2015000390A1 (en) 2017-01-03
JP2018135365A (ja) 2018-08-30
JP2016512830A (ja) 2016-05-09

Similar Documents

Publication Publication Date Title
EP3490622A4 (en) METHODS AND COMPOSITIONS FOR Wounds Healing
EP4303288C0 (en) PROCESSES FOR PRODUCING INDUSTRIAL PRODUCTS FROM VEGETABLE LIPIDS
CL2016003198A1 (es) Composiciones y métodos para empacar productos
BR112016013485A2 (pt) Método para preparar um produto lácteo tendo teor estável de galacto-oligossacarídeo(s)
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
MX2020009444A (es) Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion.
BR112017025427A2 (pt) composição farmacêutica oral
MX2016015464A (es) Composicion farmaceutica oral de isotretinoina.
IL271788A (en) Compounds and methods for trans-membrane transfer of molecules
CO2017004650A2 (es) Método de ajuste de la composición de productos de cromatografía
BR112015014870A2 (pt) método para embalar produtos e aparelho para embalar produtos
BR112015023678A2 (pt) métodos e aparelho para produzir meios pontuados, e artigo e composições que resultam dos mesmos
BR112015001564A2 (pt) métodos para a remoção de um ou mais componentes de uma composição ou composições.
MA40447A (fr) Composition pharmaceutique orale d'isotrétinoïne
ZA201804525B (en) Gypsum product composition, gypsum products, and a method for using a compound in gypsum board
DK3086653T3 (da) Fremgangsmåde til fremstilling af en lipidsammensætning uden palmeolie, anvendelse deraf i et fødevareprodukt
MA40312A (fr) Composition pharmaceutique orale d'isotrétinoïne
BR112019002729A2 (pt) composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólida
SG11201505385VA (en) Pharmaceutical composition in the form of a tabletand a method for producing same
BR112017006613A2 (pt) composição herbicida e processo da mesma
BR112016030705B8 (pt) Lipídeo de planta extraído e composição compreendendo o referido lipídeo
HUP1400025A1 (en) New dhydro-oxazinobenzodiazepine compounds a process for their preparation and pharmaceutical compositions containing them
MX2016002198A (es) Proceso para la preparación de un compuesto.
MX2015012843A (es) Agentes quelantes de precursores de producto final de glicacion avanzada (age).
BR112016019395A2 (pt) composição